Hepatitis A - Pipeline Review, H1 2016

Date: April 30, 2016
Pages: 32
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H43893D49F8EN
Leaflet:

Download PDF Leaflet

Hepatitis A - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Hepatitis A - Pipeline Review, H1 2016’, provides an overview of the Hepatitis A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hepatitis A
  • The report reviews pipeline therapeutics for Hepatitis A by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatitis A therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatitis A
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis A
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis A pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hepatitis A Overview
Therapeutics Development
Pipeline Products for Hepatitis A - Overview
Pipeline Products for Hepatitis A - Comparative Analysis
Hepatitis A - Therapeutics under Development by Companies
Hepatitis A - Therapeutics under Investigation by Universities/Institutes
Hepatitis A - Pipeline Products Glance
Late Stage Products
Early Stage Products
Hepatitis A - Products under Development by Companies
Hepatitis A - Products under Investigation by Universities/Institutes
Hepatitis A - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Hepatitis A - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Molecule Type
Drug Profiles
(hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(hepatitis A + hepatitis B) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hepatitis A + hepatitis B vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hepatitis A - Recent Pipeline Updates
Hepatitis A - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hepatitis A, H1 2016
Number of Products under Development for Hepatitis A - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
Hepatitis A - Pipeline by Sinovac Biotech Ltd., H1 2016
Hepatitis A - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Hepatitis A Therapeutics - Recent Pipeline Updates, H1 2016
Hepatitis A - Dormant Projects, H1 2016

LIST OF FIGURES

Number of Products under Development for Hepatitis A, H1 2016
Number of Products under Development for Hepatitis A - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
Skip to top


Hepatic Encephalopathy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 64 pages
Hepatitis B - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 385 pages

Ask Your Question

Hepatitis A - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: